Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdx505PMID 29045554PMCID PMC5834075
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  2017cited by this paper
• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors

  2017cited by this paper
• A phase I study of carboplatin and talazoparib in patients with and without DNA repair mutations.

  2017cited by this paper
• PARP inhibitors in BRCA mutation-associated ovarian cancer.

  2015cited by this paper
• TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

  2015cited by this paper
• Rationale for the combination of veliparib with platinum-based chemotherapy.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

  2014cited by this paper
• 246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism

  2014cited by this paper
• Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).

  2014cited by this paper
• Mechanisms of resistance to PARP inhibitors--three and counting.

  2013cited by this paper
• The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

  2013cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.

  2012cited by this paper
• P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

  2011cited by this paper
• A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

  2010cited by this paper
• ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

  2007cited by this paper
• Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

  2006cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• The PARP superfamily

  2004cited by this paper
• How many more breast cancer predisposition genes are there?

  1999cited by this paper

• Bridging molecular insights and clinical application: non-coding RNAs, targeted drug delivery, and metastatic breast cancer therapy

  2025cites this paper
• Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis

  2025cites this paper
• Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review

  2025cites this paper
• Unmatched Cell Line Collections Are Not Optimal for Identification of PARP Inhibitor Response and Drug Synergies

  2025cites this paper
• Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis

  2025cites this paper
• PARP inhibitor-based combination therapies: enriching synergistic forces against BRCA-mutated metastatic breast cancer

  2025cites this paper
• Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies

  2025cites this paper
• A potent Bioorganic azapodophyllotoxin derivative Suppresses tumor Progression in Triple negative breast Cancer: An Insight into its Inhibitory effect on tubulin polymerization and Disruptive effect on microtubule assembly.

  2024cites this paper
• Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis

  2024cites this paper
• Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer

  2024cites this paper
• PARP Inhibitors for Breast Cancer Treatment: A Review.

  2024cites this paper
• Cisplatin in the era of PARP inhibitors and immunotherapy.

  2024cites this paper
• Predicting drug outcome of population via clinical knowledge graph

  2024cites this paper
• Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer

  2024cites this paper
• Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms

  2024cites this paper
• Veliparib: Analytical Tools and Process Design Strategies for the Control of Mutagenic Impurities and Other Drug Substance Critical Quality Attributes

  2024cites this paper
• Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.

  2024cites this paper
• DNA damage response in breast cancer and its significant role in guiding novel precise therapies

  2024cites this paper
• A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)

  2023cites this paper
• A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM)

  2023cites this paper
• Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations

  2023cites this paper
• A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

  2023cites this paper
• Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges.

  2023cites this paper
• Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials

  2023cites this paper
• Current approaches to systemic treatment of BRCA-associated triple-negative breast cancer

  2023cites this paper
• Das BRCA-like-Mammakarzinom profitiert von Cisplatin plus Veliparib; Ergebnisse der S1416-Phase-II-Studie

  2023cites this paper
• Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship.

  2023cites this paper
• DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review

  2023cites this paper
• Unifying targeted therapy for leukemia in the era of PARP inhibition.

  2023cites this paper
• Alpha-ketoglutarate-dependent enzymes in breast cancer and therapeutic implications.

  2023cites this paper
• Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors.

  2023cites this paper
• An overview of the research progress of BRCA gene mutations in breast cancer.

  2023cites this paper
• Targeting DNA damage repair precision medicine strategies in cancer.

  2023cites this paper
• Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment

  2023cites this paper
• Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis

  2023cites this paper
• Efficacy and safety of treatment regimens for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/BRCA2 pathogenic variants: A network meta-analysis

  2023cites this paper
• Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis

  2023cites this paper
• Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2023cites this paper
• Systemic Therapy for Hereditary Breast Cancers.

  2023cites this paper
• Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

  2022cites this paper
• Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway

  2022cites this paper
• Perspectives on the role of breast cancer susceptibility gene in breast cancer

  2022cites this paper
• Evolving DNA repair synthetic lethality targets in cancer

  2022cites this paper
• The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022

  2022cites this paper
• NAD+ metabolism in peripheral neuropathic pain.

  2022cites this paper
• PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond

  2022cites this paper
• Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation

  2022cites this paper
• Opinion: PARP inhibitors in cancer—what do we still need to know?

  2022cites this paper
• Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?

  2022cites this paper
• Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management

  2022cites this paper
• Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer

  2022cites this paper
• PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis.

  2022cites this paper
• Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets

  2022cites this paper
• Exposure‐Response Model With Time‐Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA‐Mutated Advanced Breast Cancer (BROCADE3) Trial

  2022cites this paper
• Veliparib for the treatment of solid malignancies

  2022cites this paper
• Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer

  2022cites this paper
• Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives.

  2022cites this paper
• Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer

  2022cites this paper
• Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.

  2021cites this paper
• BRCA testing and outcomes in women with breast cancer

  2021cites this paper
• PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.

  2021cites this paper
• A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.

  2021cites this paper
• DNA damage response inhibitors: An avenue for TNBC treatment.

  2021cites this paper
• Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer

  2021influential citation
• The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?

  2021cites this paper
• PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival

  2021cites this paper
• Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.

  2021cites this paper
• Overview of recent advances in metastatic triple negative breast cancer

  2021cites this paper
• Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer

  2021cites this paper
• Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.

  2021cites this paper
• PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.

  2021cites this paper
• A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study

  2021cites this paper
• Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

  2021cites this paper
• Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis

  2021cites this paper
• Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

  2021cites this paper
• Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

  2021cites this paper
• Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

  2021cites this paper
• Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies

  2021cites this paper
• Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.

  2021cites this paper
• Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.

  2021cites this paper
• Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer

  2021cites this paper
• Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations

  2021cites this paper
• Breast Cancer Treatments: Updates and New Challenges

  2021cites this paper
• Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

  2021cites this paper
• Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review

  2021cites this paper
• A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases

  2021cites this paper
• Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story

  2021cites this paper
• Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair.

  2021cites this paper
• Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance

  2021cites this paper
• BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies

  2021cites this paper
• Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.

  2021cites this paper
• Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review

  2021influential citation
• Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer

  2021cites this paper
• Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

  2021cites this paper
• New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.

  2021cites this paper
• BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

  2020cites this paper
• Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

  2020cites this paper
• Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer

  2020cites this paper